Neurofilament light chain marks severity of papilledema in idiopathic intracranial hypertension.
CSF opening pressure
Idiopathic intracranial hypertension
Neurofilament light chain
Papilledema
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
18
05
2022
accepted:
10
01
2023
medline:
15
5
2023
pubmed:
24
1
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Neurofilament light chain (NfL) reflects axonal damage in neurological disorders. It has recently been evaluated in idiopathic intracranial hypertension (IIH). A biomarker indicating the severity of optic nerve damage in IIH could support diagnostic accuracy and therapeutic decisions. We retrospectively reviewed NfL concentrations in the cerebrospinal fluid (CSF) of 35 IIH patients and 12 healthy controls, who had received diagnostic workup for IIH in our clinic. The diagnosis of IIH was made according to the modified Friedman criteria for IIH and for IIH without papilledema Friedman DI et al Neurol 81:1159-1165 (2013) [1]. NfL in the CSF (CSF-NfL) was correlated with the severity of papilledema and with CSF opening pressure. CSF-NfL correlated with CSF opening pressure at the time of collection. In patients with IIH and moderate or severe papilledema, CSF-NfL was significantly increased compared to patients with mild or no papilledema. Healthy controls with raised intracranial pressure showed no relevant elevation of CSF-NfL. CSF-NfL appears to correlate with the severity of papilledema in IIH and with CSF opening pressure and may therefore be a predictor of optic nerve damage in IIH patients.
Sections du résumé
BACKGROUND
BACKGROUND
Neurofilament light chain (NfL) reflects axonal damage in neurological disorders. It has recently been evaluated in idiopathic intracranial hypertension (IIH). A biomarker indicating the severity of optic nerve damage in IIH could support diagnostic accuracy and therapeutic decisions.
METHODS
METHODS
We retrospectively reviewed NfL concentrations in the cerebrospinal fluid (CSF) of 35 IIH patients and 12 healthy controls, who had received diagnostic workup for IIH in our clinic. The diagnosis of IIH was made according to the modified Friedman criteria for IIH and for IIH without papilledema Friedman DI et al Neurol 81:1159-1165 (2013) [1]. NfL in the CSF (CSF-NfL) was correlated with the severity of papilledema and with CSF opening pressure.
RESULTS
RESULTS
CSF-NfL correlated with CSF opening pressure at the time of collection. In patients with IIH and moderate or severe papilledema, CSF-NfL was significantly increased compared to patients with mild or no papilledema. Healthy controls with raised intracranial pressure showed no relevant elevation of CSF-NfL.
CONCLUSION
CONCLUSIONS
CSF-NfL appears to correlate with the severity of papilledema in IIH and with CSF opening pressure and may therefore be a predictor of optic nerve damage in IIH patients.
Identifiants
pubmed: 36689008
doi: 10.1007/s10072-023-06616-z
pii: 10.1007/s10072-023-06616-z
pmc: PMC10175309
doi:
Substances chimiques
neurofilament protein L
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2131-2135Informations de copyright
© 2023. The Author(s).
Références
Balcer LJ, Liu GT, Forman S et al (1999) Idiopathic intracranial hypertension: relation of age and obesity in children. Neurol 52:870 LP – 870. https://doi.org/10.1212/WNL.52.4.870
doi: 10.1212/WNL.52.4.870
Wall M (2010) Idiopathic intracranial hypertension. Neurol Clin 28:593–617. https://doi.org/10.1016/j.ncl.2010.03.003
doi: 10.1016/j.ncl.2010.03.003
pubmed: 20637991
pmcid: 2908600
Galvin JA, Van Stavern GP (2004) Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 223:157–160. https://doi.org/10.1016/j.jns.2004.05.009
doi: 10.1016/j.jns.2004.05.009
pubmed: 15337617
Durcan PJ, Corbett JJ, Wall M (1988) The incidence of pseudotumor cerebri: population studies in Iowa and Louisiana. Arch Neurol 45:875–877. https://doi.org/10.1001/archneur.1988.00520320065016
doi: 10.1001/archneur.1988.00520320065016
pubmed: 3395261
Markey KA, Mollan SP, Jensen RH, Sinclair AJ (2016) Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 15:78–91. https://doi.org/10.1016/S1474-4422(15)00298-7
doi: 10.1016/S1474-4422(15)00298-7
pubmed: 26700907
Ball AK, Clarke CE (2006) Idiopathic intracranial hypertension. Lancet Neurol 5:433–442. https://doi.org/10.1016/S1474-4422(06)70442-2
doi: 10.1016/S1474-4422(06)70442-2
pubmed: 16632314
Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurol 81:1159–1165. https://doi.org/10.1212/WNL.0b013e3182a55f17
doi: 10.1212/WNL.0b013e3182a55f17
Takkar A, Goyal MK, Bansal R, Lal V (2018) Clinical and neuro-ophthalmologic predictors of visual outcome in idiopathic intracranial hypertension. Neuro-Ophthalmology 42:201–208. https://doi.org/10.1080/01658107.2017.1400570
doi: 10.1080/01658107.2017.1400570
pubmed: 30042789
pmcid: 6056212
Rebolleda G, Muñoz-Negrete FJ (2009) Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography. Invest Ophthalmol Vis Sci 50:5197–5200. https://doi.org/10.1167/iovs.08-2528
doi: 10.1167/iovs.08-2528
pubmed: 19011007
Friedman DI (2019) Contemporary management of the pseudotumor cerebri syndrome. Expert Rev Neurother 19:881–893. https://doi.org/10.1080/14737175.2019.1660163
doi: 10.1080/14737175.2019.1660163
pubmed: 31478394
Yri HM, Wegener M, Sander B, Jensen R (2012) Idiopathic intracranial hypertension is not benign: a long-term outcome study. J Neurol 259:886–894. https://doi.org/10.1007/s00415-011-6273-9
doi: 10.1007/s00415-011-6273-9
pubmed: 22008872
Hatem CF, Yri HM, Sørensen AL et al (2018) Long-term visual outcome in a Danish population of patients with idiopathic intracranial hypertension. Acta Ophthalmol 96:719–723. https://doi.org/10.1111/aos.13664
doi: 10.1111/aos.13664
pubmed: 29405582
Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577–589. https://doi.org/10.1038/s41582-018-0058-z
doi: 10.1038/s41582-018-0058-z
pubmed: 30171200
Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987:25–31. https://doi.org/10.1016/S0006-8993(03)03219-0
doi: 10.1016/S0006-8993(03)03219-0
pubmed: 14499942
Modvig S, Degn M, Sander B et al (2016) Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Multiple sclerosis (Houndmills, Basingstoke, England) 22:590–598. https://doi.org/10.1177/1352458515599074
doi: 10.1177/1352458515599074
pubmed: 26283696
Beier D, Korsbæk JJ, Madsen JS et al (2020) Neurofilament light chain as biomarker in idiopathic intracranial hypertension. Cephalalgia 40:1346–1354. https://doi.org/10.1177/0333102420944866
doi: 10.1177/0333102420944866
pubmed: 32727204
Sheils CR, Fischer WS, Hollar RA et al (2018) The relationship between optic disc volume, area, and Frisén score in patients with idiopathic intracranial hypertension. Am J Ophthalmol 195:101–109. https://doi.org/10.1016/j.ajo.2018.07.032
doi: 10.1016/j.ajo.2018.07.032
pubmed: 30081012
pmcid: 6214729
Peng L, Bi C, Xia D et al (2019) Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Mult Scler Relat Disord 30:123–128. https://doi.org/10.1016/J.MSARD.2019.02.009
doi: 10.1016/J.MSARD.2019.02.009
pubmed: 30771578
von Widekind S, Alagaratnam J, de Francesco D et al (2020) Correlation between cerebrospinal fluid and blood neurofilament light protein: a systematic review and meta-analysis. Alzheimer’s Dement 16:e041018. https://doi.org/10.1002/ALZ.041018
doi: 10.1002/ALZ.041018